| Stage | ARXS | % of rev | CNP | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $564M | 100.00% | $2.2B | 100.00% | CNP ×3.88 |
| Gross profit | $306M | 54.27% | $1.3B | 57.33% | CNP +3.1pp |
| Operating income | $133M | 23.66% | $667M | 30.44% | CNP +6.8pp |
| Pre-tax income | $120M | 21.23% | $413M | 18.85% | ARXS +2.4pp |
| Net income | $84M | 14.84% | $331M | 15.11% | CNP +0.3pp |
| Stage | ARXS | CNP | Gap · A − B |
|---|---|---|---|
| Revenue | $564M100.00% | $2.2B100.00% | CNP ×3.88 |
| Gross profit | 54.27%$306M | 57.33%$1.3B | CNP +3.1pp |
| Operating income | 23.66%$133M | 30.44%$667M | CNP +6.8pp |
| Pre-tax income | 21.23%$120M | 18.85%$413M | ARXS +2.4pp |
| Net income |
| 14.84%$84M |
| 15.11%$331M |
| CNP +0.3pp |
None
No disclosed counterparties: ARXS.